News articles about Rhythm Pharmaceuticals (NASDAQ:RYTM) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.1970903795329 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Pacemaker Industry 2018 – Growth Analysis | End users | Synopsis | Top Vendors and Forecast to 2022 (digitaljournal.com)
- Rhythm Pharmaceuticals Inc’s Lock-Up Period To End on April 3rd (NASDAQ:RYTM) (americanbankingnews.com)
- Rhythm Pharmaceuticals (RYTM) Upgraded to “Hold” by BidaskClub (americanbankingnews.com)
- Innovation in Global Cardiac Resynchronization Therapy (CRT Devices): Market to See Major Growth in Next Five Years (medgadget.com)
- D.C. drug company faces a new generics threat (bizjournals.com)
A number of research firms recently commented on RYTM. BidaskClub cut shares of Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Monday, February 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $31.25.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings data on Monday, March 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.14. research analysts predict that Rhythm Pharmaceuticals will post -2.3 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Rhythm Pharmaceuticals (RYTM) Stock Price” was originally reported by WKRB News and is owned by of WKRB News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.wkrb13.com/2018/04/02/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-rhythm-pharmaceuticals-rytm-stock-price.html.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.